Novo Nordisk Dividend
Dividend criteria checks 3/6
Novo Nordisk is a dividend paying company with a current yield of 1.11% that is well covered by earnings.
Key information
1.1%
Dividend yield
50%
Payout ratio
Industry average yield | 2.4% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | US$20.10 |
Dividend yield forecast in 3Y | 1.9% |
Recent dividend updates
Recent updates
The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23Novo Nordisk: Dominating In Diabetes And Obesity
Jun 05Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity
May 23Novo Nordisk: Attractive Market But Likely No Margin Of Safety
Feb 15Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg
Feb 07Stability and Growth of Payments
Fetching dividends data
Stable Dividend: NVO's dividend payments have been volatile in the past 10 years.
Growing Dividend: NVO's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
Novo Nordisk Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (NVO) | 1.1% |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.7% |
Industry Average (Pharmaceuticals) | 2.4% |
Analyst forecast in 3 Years (NVO) | 1.9% |
Notable Dividend: NVO's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.53%).
High Dividend: NVO's dividend (1.11%) is low compared to the top 25% of dividend payers in the US market (4.73%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (50.4%), NVO's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: At its current cash payout ratio (83%), NVO's dividend payments are covered by cash flows.